secwatch.observer — SEC 8-K summary
======================================

Issuer:     MoonLake Immunotherapeutics (MLTX)
CIK:        0001821586
Form:       8-K
Filed at:   2023-06-29T23:59:59+00:00
Accession:  0001628280-23-023905
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MoonLake raises $460M in offering; Phase 2 MIRA trial meets primary endpoint with HiSCR75 at week 12
--------------------------------------------------------------------------------

- Priced 9.2M Class A ordinary shares at $50/sh (8M firm + 1.2M option) for $460M gross proceeds.
- Phase 2 MIRA trial (234 patients) met HiSCR75 primary endpoint: 120mg dose had 29 ppt delta to placebo (p=0.0002).
- HiSCR50 delta 38 ppt (p<0.0001); secondary endpoints including HiSCR90, IHS4, pain, quality of life all significant.
- SLK safety consistent with prior IL-17 inhibitor profile; no new signals observed.
- Entered global royalty-bearing license with RCT for Pichia pastoris manufacturing process for SLK.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1821586/000162828023023905/0001628280-23-023905-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1821586/000162828023023905/mltx-20230627.htm
  HTML page:      https://secwatch.observer/filing/0001628280-23-023905

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer